{{Rsnum
|rsid=1715364
|Gene=SLC23A2
|Chromosome=20
|position=4918250
|Orientation=plus
|GMAF=0.3999
|Gene_s=SLC23A2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 18.6 | 39.8 | 41.6
| HCB | 38.7 | 46.7 | 14.6
| JPT | 55.8 | 32.7 | 11.5
| YRI | 73.5 | 25.2 | 1.4
| ASW | 50.9 | 47.4 | 1.8
| CHB | 38.7 | 46.7 | 14.6
| CHD | 52.3 | 40.4 | 7.3
| GIH | 21.8 | 60.4 | 17.8
| LWK | 59.1 | 34.5 | 6.4
| MEX | 19.0 | 62.1 | 19.0
| MKK | 48.1 | 47.4 | 4.5
| TSI | 26.5 | 49.0 | 24.5
| HapMapRevision=28
}}{{PMID Auto
|PMID=24578608
|Title=Genetic Polymorphisms in SLC23A2 as Predictive Biomarkers of Severe Acute Toxicities after Treatment with a Definitive 5-Fluorouracil/Cisplatin-Based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma
|OA=1
}}

{{PMID Auto
|PMID=18636124
|Title=Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}